Advice
following an abbreviated submission:
budesonide gastro-resistant granules (Budenofalk®) is accepted for use within NHS Scotland.
Indication under review: induction of remission in patients with mild to moderate active Crohn’s disease affecting the ileum and/or ascending colon.
Budesonide gastro-resistant granules provide a once daily alternative to budesonide gastro-resistant 3mg capsules three times daily at no additional cost. The granules may have advantages for patients who have difficulty swallowing.
Download detailed advice94KB (PDF)
Medicine details
- Medicine name:
- budesonide gastro-resistant granules (Budenofalk®)
- SMC ID:
- 970/14
- Indication:
- Induction of remission in patients with mild to moderate active Crohn' s disease affecting the ileum and/or ascending colon.
- Pharmaceutical company
- Dr Falk Pharma UK
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 09 June 2014